Datavant to acquire real-world evidence company Aetion to boost its life sciences business

Datavant announced its acquisition of real-world evidence (RWE) company Aetion to enhance its data exchange and analytics capabilities, aiming to create a comprehensive, end-to-end RWE platform. The move positions Datavant as a more direct competitor in the real-world data space, expanding its footprint beyond data connectivity into RWE analytics by integrating Aetion’s scientific expertise and regulatory-grade evidence generation capabilities. This strategic expansion aligns with growing demand for tokenized, scalable RWE in clinical development and post-market surveillance.

Read the full article in Fierce Healthcare here.